The role of cytokines in cardiac surgery

International Journal of Cardiology

Volumn 53, Issue SUPPL., 1996, Pages

  Tønnesen, Else ^a   Christensen, Vibeke Brix ^a   Toft, Palle ^b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cardiac surgery; Cardiopulmonary bypass; Cytokines; Interleukin; Tumour necrosis factor

Indexed keywords

ALFENTANIL; ANESTHETIC AGENT; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; ISOFLURANE; OPIATE; PROPOFOL; TUMOR NECROSIS FACTOR ALPHA;

CARDIOPULMONARY BYPASS; HEART SURGERY; HORMONE RELEASE; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0342738009     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/0167-5273(96)02568-5     Document Type: Article

References (77)

1. Kehlet H. The stress response to surgery. Release mechanisms and the modifying effect of pain relief. Acta Chir Scand 1989; 55: 28-28.
2. Slade MS, Simmons RL, Yunis E, Greenberg LJ. Immunodepression after major surgery in normal patients. Surgery 1975; 78: 363-372.
3. Salo M. Effects of anaesthesia and surgery on the immune response. Acta Anaesthesiol Scand 1992; 36: 201-220.
4. Stevenson GW, Hall S, Rudnick S, Seleny FL, Stevenson HC. The effect of anesthetic agents on human immune response. Anesthesiology 1990; 722: 542-552.
5. Tønnesen E. Immunological aspects of anaesthesia and surgery. With special reference to NK cells. Dan Med Bull 1989; 36: 263-281.
6. Imura H, Fukata J, Mori T. Cytokines and endocrine function: an interaction between the immune and neuroendocrine systems. Clin Endocrinol 1991; 35: 107-115.
7. Del Rey A, Besedovsky HO. Metabolic and neuroendocrine effects of pro-inflammatory cytokines. Eur J Clin Invest 1992; 22: 10-15.
8. Bendtzen K. The polypeptide mediator network of the immune system. In: Ullmann V, Dalhoff A. eds. Significance of Cytokines in the Treatment of Infectious Diseases. New York: Gustav Fischer Verlag 1993; 97-110.
9. Waage. The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1 and fatal outcome. J Exp Med 1989; 169: 333-338.
10. Kirklin JK, Westaby S, Blackstone EH, Kirklin JW, Chenoweth DE, Pacifico AD. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1983; 86: 845-857.
11. Butler J, Rocker GM, Westaby S. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1993; 55: 552-559.
12. Knudsen F, Andersen LW. Immunological aspects of cardiopulmonary bypass. J Cardiothorac Anesth 1990; 4: 245-258.
13. Casey LC. Role of cytokines in the pathogenesis of cardiopulmonary-induced multisystem organ failure. Ann Thorac Surg 1993; 56: 92-96.
14. Bernard C, Tedgui A. Cytokine network and the vessel wall. Insights into septic shock pathogenesis. Eur Cytokine Netw 1992; 3: 19-33.
15. Levy JH, Kelly AB. Inflammation and cardiopulmonary bypass. Can J Anaesth 1993; 40: 1009-1015.
16. Downing SW, Edmunds LHJ. Release of vasoactive substances during cardiopulmonary bypass. Ann Thorac Surg 1992; 54: 1236-1243.
17. Bendtzen K. Immune hormones (cytokines); pathogenic role in autoimmune rheumatic diseases and endocrine diseases. Autoimmunity 1989; 2: 177-189.
18. Bendtzen K. Cytokines and natural regulators of cytokines. Immunol Lett 1994; 43: 111-123.
19. Bendtzen K. Interleukin 1, interleukin 6 and tumor necrosis factor in infection, inflammation and immunity. Immunol Lett 1988; 19: 183-192.
20. Bendtzen K. Clinical significance of cytokines. Natural and therapeutic regulation. Semin Clin Immunol 1991; 3: 5-13.
21. Okusawa S, Gelfand JA, Ikejima T, Connolly RJ, Dinarello CA. Interleukin-1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest 1988; 81: 1162-1172.
22. Yoshizumi M, Perrella MA, Burnett JC, Lee M-E. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res 1993; 73: 205-209.
23. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990; 265: 621-636.
24. Le JM, Vilcek J. Interleukin 6: a multifunctional cytokine regulating immune reactions and the acute phase protein response. Lab Invest 1989; 61: 588-602.
25. Butler J, Chong GL, Baigrie RJ, Pillai R, Westaby S, Rocker GM. Cytokine responses to cardiopulmonary bypass with membrane and bubble oxygenation. Ann Thorac Surg 1992; 53: 833-838.
26. Shenkin A, Fraser WD, Series J, et al. The serum interleukin 6 response to elective surgery. Lymphokine Res 1989; 8: 123-127.
27. Pullicino EA, Carli F, Poole S, Raferty B, Malik STA, Elia M. The relationship between the circulating concentration of interleukin 6 (1L-6), tumor necrosis factor (TNF) and the acute phase response to elective surgery and accidental injury. Lymphokine Res 1990; 9: 231-238.
28. Abe K, Nishimura M, Sakakibara T. Interleukin-6 and tumour necrosis factor during cardiopulmonary bypass. Can J Anaesth 1994; 41: 876-877.
29. Cruickshank AM, Fraser WD, Burns HJG, Van Damme J, Shekin A. Response of interleukin-6 in patients undergoing elective surgery of varying severity. Clin Sci 1990; 79: 161-165.
30. Ohzato H, Yoshizaki K, Nishimoto N. Interleukin-6 as a new indicator of inflammatory status: detection of serum levels of interleukin-6 and C-reactive protein after surgery. Surgery 1992; 111: 201-209.
31. Oka Y, Murata A, Nishijima J, et al. Circulating interleukin 6 as a useful marker for predicting postoperative complications. Cytokine 1992; 4: 298-304.
32. Baigre RJ, Lamont PM, Kwiatkowski D. Systemic cytokine response after major surgery. Br J Surg 1992; 79: 757-760.
33. Kawamura T, Wakusawa R, Okada K, Inada S. Elevation of cytokines during open heart surgery with cardiopulmonary bypass: participation of interleukin 8 and 6 in reperfusion injury. Can J Anaesth 1993; 40: 1016-1021.
34. Almdahl SM, Waage A, Ivert T, Vaage J. Release of bioactive interleukin-6 but not of tumor necrosis factor-alfa after elective cardiopulmonary bypass. Perfusion 1993; 8: 233-238.
35. Steinberg JB, Kapelanski DP, Olson JD, Weiler JM. Cytokine and complement levels in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1993; 106: 1008-1016.
36. Frering B, Philip I, Dehoux M, Rolland C, Langlois JM, Desmonts JM. Circulating cytokines in patients undergoing normothermic cardiopulmonary bypass. J Thorac Cardiovasc Surg 1994; 108: 636-641.
37. Inaba H, Kochi A, Yorozu S. Suppression by methylprednisolone of augmented plasma endotoxin-like activity and interleukin-6 during cardiopulmonary bypass. Br J Anaesth 1994; 72: 348-350.
38. Tønnesen E, Wanscher M, Höhndorf K, et al. Effect of methylprednisolone on the cytokine response in patients undergoing lung surgery. Acta Anaesthesiol Scand 1993; 37: 410-414.
39. Molloy RG, Mannick JA, Rodrick ML. Cytokines, sepsis and immunomodulation. Br J Surg 1993; 80: 289-297.
40. Beutler B, Cerami A. Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature 1986; 320: 584-588.
41. Ertel W, Morrison MH, Ayala A, Perrin MM, Chaudry IH. Blockade of prostaglandin production increases cachectin synthesis and prevents depression of macrophage functions after hemorrhagic shock. Ann Surg 1991; 213: 265-271.
42. Beutler B, Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med 1987; 316: 379-385.
43. Jansen NJ, van Oeveren W, van den Broek L, et al. Inhibition by dexamethasone of the reperfusion phenomena in cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991; 102: 515-525.
44. Tönz M, Mihaljevic T, von Segesser LK, et al. Normothermia versus hypothermia during cardiopulmonary bypass: a randomized, controlled trial. Ann Thorac Surg 1995; 59: 137-143.
45. Jansen NJ, van Oeveren W, Gu YJ, van Vliet MH, Eijsman L, Wildevuur CR. Endotoxin release and tumor necrosis factor formation during cardiopulmonary bypass. Ann Thorac Surg 1992; 54: 744-747.
46. Haeffner-Cavaillon N, Roussellier N, Ponzio O, et al. Induction of interleukin-1 production in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1989; 98: 1100-1106.
47. Markewitz A, Faist E, Lang S, Endres S, Hultner L, Reichart B. Regulation of acute phase response after cardiopulmonary bypass by immunomodulation. Ann Thorac Surg 1993; 55: 389-394.
48. Butler J, Pillai R, Rocker GM, Westaby S, Parker D, Shale DJ. Effect of cardiopulmonary bypass on systemic release of neutrophil elastase and tumor necrosis factor. J Thorac Cardiovasc Surg 1993; 105: 25-30.
49. Hansen PR, Svendsen JH, Hoyer S, Kharazmi A, Bendtzen K, Haunso S. Tumor necrosis factor-alpha increases myocardial microvascular transport in vivo. Am J Physiol 1994; 266: H60-H67.
50. Houssiau FA, Coulie PG, Van Snick J. Distinct roles of IL-1 and IL-6 in human T cell activation. J Immunol 1989; 143: 2520-2524.
51. Cavaillon JM, Munoz C, Fitting C, Misset B, Carlet J. Circulating cytokines: the tip of the iceberg? Circ Shock 1992; 38: 145-152.
52. Kunkel SL, Standiford T, Kasahara K, Stricter RM. Interleukin-8 (IL-8): the major neutrophil chemotactic factor in the lung. Exp Lung Res 1991; 17: 17-23.
53. Metinko AP, Kunkel SL, Standiford TJ, Strieter RM. Anoxia-hyperoxia: a model of ischemia reperfusion for interleukin-8 expression by monocytes. Am Rev Respir Dis 1991; 143: [Abstract].
54. Basha MA, Kunkel SL, Rowens B, Popovich J Jr, Stricter RM. Interleukin-8 expression in HIV-dependent PCP associated neutrophilic alveolitis. Am Rev Respir Dis 1991; 143 [Abstract].
55. Van Devort AL, Danner RL. Interleukin-8 (IL-8) primes human neutrophils for enhanced production of superoxide (O2). Crit Care Med 1990; 18: 251.
56. Danner RL, Suffredini AF, Van Der Vort AL. Neutrophil activating peptide-1/Interleukin-8 concentration in human shock. Crit Care Med 1990; 18: 281.
57. Finn A, Naik S, Klein N, Levinsky RJ, Strobel S, Elliott M. Interleukin-8 release and neutrophil degranulation after pediatric cardiopulmonary bypass. J Thorac Cardiovasc Surg 1993; 105: 234-241.
58. Jorens PG, De Jongh R, De Backer W, et al. Interleukin-8 production in patients undergoing cardiopulmonary bypass. The influence of pretreatment with methylprednisolone. Am Rev Respir Dis 1993; 148: 890-895.
59. Jorens PG, Van Damme J, De Backer W, et al. Interleukin 8 (IL-8) in the bronchoalveolar lavage fluid from patients with the adult respiratory distress syndrome (ARDS) and patients at risk for ARDS. Cytokine 1992; 4: 592-597.
60. Gastl GA, Abrams JS, Nanus DM, et al. Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. Int J Cancer 1993; 55: 96-101.
61. Knolle P, Schlaak J, Uhrig A, Kemp P, Zumbuschanfelde KHM, Gerken G. Human kupffer cells secrete IL-10 in response to lipopolysaccharide (LPS) challenge. J Hepatol 1995; 22: 226-229.
62. Seitz M, Loetscher P, Dewald B, Towbin H, Gallati H, Baggiolini M. Interleukin-10 differentially regulates cytokine inhibitor and chemokine release form blood mononuclear cells and fibroblasts. Eur J Immunol 1995; 25: 1129-1132.
63. Hempel L, Körholz D, Bönig H, et al. Interleukin-10 directly inhibits the interleukin-6 production in T-cells. Scand J Immunol 1995; 41: 462-466.
64. Chernoff AE, Granowitz EV, Shapiro L, et al. A randomized, controlled trial of IL-10 in humans - inhibition of inflammatory cytokine production and immune responses. J Immunol 1995; 154: 5492-5499.
65. Gomez-Jimenez J, Martin MC, Sauri R, et al. Interleukin-10 and the monocyte/macrophage-induced inflammatory response in septic shock. J Infect Dis 1995; 171: 472-475.
66. Montz FJ, Holschneider CH, Bozuk M, Gotlieb WH, Martinezmaza O. Interleukin-10: ability to minimize postoperative intraperitoneal adhesion formation in a murine model. Fertil Steril 1994; 61: 1136-1140.
67. Derkx B, Marchant A, Goldman M, Bijlmer R, van Deventer S. High levels of interleukin-10 during the initial phase of fulminant meningococcal septic shock. J Infect Dis 1995; 171: 229-232.
68. Dinarello DA. Interleukin-1 and interleukin-1 antagonism. Blood 1991; 77: 1627-1652.
69. Ohlsson K, Björk P, Bergenfeldt M, Hageman R, Thompson RC. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990; 348: 550-552.
70. Marks JD, Marks CB, Luce JM et al. Plasma tumor necrosis factor in patients with septic shock. Am Rev Respir Dis 1990; 141: 94-97.
71. Damas P, Reuter A, Gysen P, Demonty J. Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med 1989; 17: 975-978.
72. Hack CE, De Groot ER, Felt-Bersma RJF, Nuijens JH. Increased plasma levels of interleukin-6 in sepsis. Blood 1989; 74: 1704-1710.
73. Tønnesen E, Wahlgreen C. Influence of extradural and general anaesthesia on natural killer cell activity and lymphocyte subpopulations in patients undergoing hysterectomy. Br J Anaesth 1988; 60: 500-507.
74. Stanley TH, Berman L, Green O, Robertson D. Plasma catecholamine and cortisol responses to fentanyl-oxygen anesthesia for coronary-artery operations. Anesthesiology 1980; 53: 250-253.
75. Crozier TA, Müller JE, Quittkat D, Sydow M, Wuttke W, Kettler D. Effect of anaesthesia on the cytokine responses to abdominal surgery. Br J Anaesth 1994; 72: 280-285.
76. Stefano GB, Bilfinger TV. Human neutrophil and macrophage chemokinesis induced by cardiopulmonary bypass: loss of DAME and IL-1 chemotaxis. Neuroimmunology 1993; 47: 189-198.
77. Bilfinger TV, Fricchione G, Stefano GB. Neuroimmune implications of cardiopulmonary bypass. Adv Neuroimmunol 1993; 3: 277-288.